Variants of unknown significance (VUS) in DNA repair genes in Caucasian men with muscle invasive bladder cancer (MIBC): A case of “serendipity” pushing for a BC screening program.

M Massimo Lazzeri G Giovanni Lughezzani R Roberto Contieri P Pier Paolo Avolio V Vittorio Fasulo M Marco Paciotti G Giuseppe Chiarelli (Humanitas University, Pieve Emanuele, Italy) G Giuseppe Garofano (Humanitas University, Pieve Emanuele, Italy) G Giulia Soldà (Humanitas University, Pieve Emanuele, Italy) R Rosanna Asselta (Humanitas University, Pieve Emanuele, Italy) A Anita Capalbo P Piergiuseppe Colombo (Humanitas University, Pieve Emanuele, Italy) P Pietro Cavalli (IRCCS - Humanitas Research Hospital, Rozzano, Italy) N NicolòMaria Buffi (Humanitas University, Pieve Emanuele, Italy) A Alberto Saita P Paolo Casale H Hurle Rodolfo (IRCCS - Humanitas Research Hospital, Rozzano, Italy)

Abstract

683 Background: In 2021 we started an enhanced PCa screening in healthy Caucasian men with germline DNA repair pathogenic variants. Over 109 enrolled men, we found two naïve patients with bladder cancer (BC), but none with PCa. This observation prompted us to investigate the prevalence of germline pathogenic variants in patients with BC and suggest genetic counselling, testing and screening for healthy relatives of subject with BC. Methods: This is a prospective ongoing study aiming to detect, by exome analysis, the prevalence of germline pathogenic (PV), likely pathogenic (LPV) variants and variant of unknown significance (VUS) in patients with BC attending the urological department from January 2024. The following DNA repair genes were considered: ATM , ATR , MRE11A , BAP1 , BARD1 , BRCA1 , NBN , BRCA2 , PALB2 , BRIP1 , CHEK2 , RAD51C , FAM175A , RAD51D , GEN1 , and XRCC1 , plus mismatch repair genes MLH1 , PMS2 , MSH2 , and MSH6 . Healthy relatives (>35 years) of patients tested positive, are being offered genetic counselling, testing and finally screening for early detection of BC. Screening consists of urine analysis, urine cytology, ultrasound abdominal assessment and cystoscopy, when indicated, every year. The study is financed/supported by Associazione Italiana per la Ricerca sul Cancro (AIRC): Protocol ICH-2812, code IG 2020-ID-25027. Results: From January to March 2024, 41 patients with BC (25 non-muscle invasive, NMIBC and 16 muscle invasive, MIBC) were tested. Overall, we found 919 variants in the 20 DNA repair genes analysed, of which 385 rare (minor allele frequency <1%). No PV and LPV were identified, while 18 VUS were found in 12 patients (29.3%; mean age 66.75 SD 11.75 vs. 69.82 SD 13.71 in negative).The reported variants affected the following genes: ATM (4); ATR (3); BARD1 (3); PMS2 (2), and BRCA2 , CHEK2 , MSH6 , NBN , PALB2 , GEN1 (1 variant each). Interestingly, all variants were found in MIBC patients or HG-NMIBC, whereas no variant was observed in low-grade NMIBC (p< 0.00001, Fisher exact test). Patients with multiple variants had a significant lower age: mean age 58.16 SD 9.02 p<0.01. Conclusions: According to Merriam-Webster dictionary “serendipity” is the phenomenon of finding valuable or agreeable things not sought for. Starting from a PCa screening in healthy men, although no clearly pathogenic variants were identified in our BC cohort, we found the presence of about 30% of VUS linked to aggressive cancers and patient low age. Those findings challenge the current (no)recommendation on genetic counselling and testing in this setting and strongly support the urgent need to raise awareness of genetic risk for BC and to design effective public health promotion policies.

Article Details

Volume / Issue Vol. 43, Issue 5_suppl
Published February 10, 2025
Pages 683-683
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (17)

M

Massimo Lazzeri

G

Giovanni Lughezzani

R

Roberto Contieri

P

Pier Paolo Avolio

V

Vittorio Fasulo

M

Marco Paciotti

G

Giuseppe Chiarelli

Humanitas University, Pieve Emanuele, Italy

G

Giuseppe Garofano

Humanitas University, Pieve Emanuele, Italy

G

Giulia Soldà

Humanitas University, Pieve Emanuele, Italy

R

Rosanna Asselta

Humanitas University, Pieve Emanuele, Italy

A

Anita Capalbo

P

Piergiuseppe Colombo

Humanitas University, Pieve Emanuele, Italy

P

Pietro Cavalli

IRCCS - Humanitas Research Hospital, Rozzano, Italy

N

NicolòMaria Buffi

Humanitas University, Pieve Emanuele, Italy

A

Alberto Saita

P

Paolo Casale

H

Hurle Rodolfo

IRCCS - Humanitas Research Hospital, Rozzano, Italy